Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2014

01-08-2014 | Review Article

Vaccination in the Elderly: What Can Be Recommended?

Authors: Pierre-Olivier Lang, Richard Aspinall

Published in: Drugs & Aging | Issue 8/2014

Login to get access

Abstract

The age-associated increased susceptibility to infectious disease would suggest that vaccination should be a route to promote healthy aging and keep our seniors autonomous and independent. While vaccination represents a cost-effective and efficient strategy at community level, the ability of the immune system to mount a protective immune response is still unpredictable at the level of the individual. Thus, at a similar age, some individuals, including the elderly, might still be ‘good’ responders while some other, even younger, would definitely fail to mount a protective response. In this review, the current burden of vaccine-preventable diseases in the aging and aged population will be detailed with the aim to identify the ideal vaccine candidates over the age of 50 years. This article will conclude with potential strategies to reduce, as best as possible, this burden and the imperative need to overcome barriers in extending current vaccine coverage towards to a lifelong vaccine schedule.
Literature
1.
Lang PO, Aspinall R. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules? Expert Rev Vaccines. 2012;11:167–76.PubMed
2.
Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, Pawelec G. Aging, frailty and age-related diseases. Biogerontology. 2010;11:547–63.PubMed
3.
4.
Lang PO, Samaras N, Samaras D. Does Vitamin D deficiency contribute to accentuate the state of vulnerability to pathogens of aging and aged adults. Eur Geriatr Med. 2013;4:59–65.
5.
Lang PO, Samaras D, Samaras N. Testosterone replacement therapy in reversing “andropause”: what is the proof-of-principle? Rejuvenation Res. 2012;15:453–65.PubMed
6.
O’Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol. 2008;252:91–110.PubMedCentralPubMed
7.
Burgess W, Liu Q, Zhou J, Tang Q, Ozawa A, VanHoy R, Arkins S, Dantzer R, Kelley KW. The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Neuroimmunomodulation. 1999;6:56–68.PubMed
8.
Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012;4:535–46.
9.
Hamza SA, Mousa SM, Taha SE, Adel LA, Samaha HE, Hussein DA. Immune response of 23-valent pneumococcal polysaccharide vaccinated elderly and its relation to frailty indices, nutritional status, and serum zinc levels. Geriatr Gerontol Int. 2012;12:223–9.PubMed
10.
Yao X, Hamilton RG, Weng NP, Xue QL, Bream JH, Li H, Tian J, Yeh SH, Resnick B, Xu X, Walston J, Fried LP, Leng SX. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29:5015–21.PubMedCentralPubMed
11.
McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012;30:2060–7.PubMedCentralPubMed
12.
Eilers R, Krabbe PFM, van Essen TG, Suijkerbuijk A, van Lier A, de Melker HE. Assessment of vaccine candidates for persons aged 50 and lder: a review. BMC Geriatr. 2013;13:32.PubMedCentralPubMed
13.
14.
Lang PO, Govind S, ten Bokum A, Kenny N, Matas E, Pitts D, Aspinall R. Immune senescence and vaccination in the elderly. Curr Topic Med Chem. 2013;20:2541–50.
15.
16.
Collerton J, Davies K, Jagger C, Kingston A, Bond J, Eccles MP, Robinson LA, Martin-Ruiz C, von Zglinicki T, James OF, Kirkwood TB. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904.PubMedCentralPubMed
17.
Strindhall J, Nilsson BO, Lofgren S, et al. No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol. 2007;42:753–61.PubMed
18.
Wikby A, Mansson IA, Johansson B, Strindhall J, Nilsson SE. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20–100 years of age. Biogerontology. 2008;9:299–308.PubMed
19.
Lelic A, Vershoor CP, Ventresca M, parsons R, Evelegh C, Bowdish D et al. The polyfunctionality of human memory CD8+ T-cells elicited by acute and chronic virus infections is not influenced by age. PLos Pathog. 2012;8:e1003076.
20.
Olivieri F, Rippo M, Prattichizzo F, Bambini L, Graciotti L, Ricchioni R, et al. Toll-like receptor signalling in “inflammaging” microRNA as new players. Immun Ageing. 2013;10:11.PubMedCentralPubMed
21.
Lang PO. Why influenza viruses continue to pose a significant threat to aging and aged populations worldwide. Curr Geriatr Rep. 2014;3:56–65.
22.
Lang PO, Bonduelle O, Benhabiles N, Combadiere B. Prior contacts with the 2000–2003 seasonal vaccines extends the 2009 pandemic A/H1N1 vaccine-specific immune protection to non-humoral compartments. Eur Geriatr Med. 2014;5:136–8.
23.
Bonduelle O, Yahia N, Siberil S, Benhabiles N, Carrat F, Krivine A, Rozenberg F, Dimitrov J, Kaveri SV, Curjol A, Tindel M, Louet M, Desert F, Launay O, Loulergue P, Badre G, Katlama C, Bricaire F, Samri A, Rousset D, van der Werf S, Jauréguiberry S, Combadiere B. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. J Immunol. 2013;191:623–31.PubMed
24.
Lang PO, Govind S, Aspinall R. Reversing T cell immunosenescence: why, who, and how. Age (Dordr). 2013;35:609–20.
25.
Govind S, Lapenna A, Lang PO, Aspinall R. Immunotherapy of immunosenescence: who, how and when. Open Longev Sci. 2012;6:56–63.
26.
Lang PO, Samaras D. Aging adults and seasonal influenza: does the vitamin D status (h)arm the body? J Aging Res. 2012;2012:806198.PubMedCentralPubMed
27.
Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis. 2011;52:911–6.PubMed
28.
Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect. 2011;13:683–9.
29.
Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA. Immunosenescence: implications for vaccination programmes in adults. Maturitas. 2011;68:322–30.PubMed
30.
John TJ, Samuel R. Herd immunity and herd effect; new insights and definition. Eur J Epidemiol. 2000;16:601–6.PubMed
31.
McGuire T, Wells KB, Bruce ML, Miranda J, Scheffer R, Durham M, Ford E, Lewis L. Burden of illness. Ment Health Serv Res. 2002;4:179–85.PubMed
32.
Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine. 2009;27:3240–4.PubMedCentralPubMed
33.
van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, Lee BY, Zadorozhny V, Brown S, Cummings D, Burke DS. Contagious diseases in the United States from 1888 to the present. N Engl J Med. 2013;369:2152–8.PubMed
34.
35.
Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev. 2011;10:389–95.PubMed
36.
Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. Am J Epidemiol. 2004;160:492–502.PubMed
37.
World Health organization (WHO). The centralized information system for infectious diseases (CISID). Geneva: WHO; 2009.
38.
Cabellos C, Verdaguer R, Olmo M, Fernández-Sabé N, Cisnal M, Ariza J, Gudiol F, Viladrich PF. Community-acquired bacterial meningitis in elderly patients: experience over 30 years. Medicine. 2009;88:115–9.PubMed
39.
Metersky ML, Dransfield MT, Jackson LA. Determining the optional pneumococcal vaccination in adults: is there a role for the pneumococcal conjugate vaccine? Chest. 2010;138:486–90.PubMed
40.
Jansen AG, Rodenburg GD, de Greef SC, Hak E, Veenhoven RH, Spanjaard L, Shouls LM, Sanders EA, van der Ende A. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27:2394–401.PubMed
41.
van Gageldonk-Lafeber AB, Bogaerts MA, Verheij RA, van der Sande MA. Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. Epidemiol Infect. 2009;137:1472–8.PubMed
42.
Falsey AR, Wlash EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis. 2002;185:1338–41.PubMed
43.
Rozenbaum MHHE, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther. 2010;32:517–32.
44.
Michel JP, Lang PO. Promoting life course vaccination. Rejuvenation Res. 2011;14:75–81.PubMed
45.
Lang PO, Michel JP. Herpes zoster vaccine: what are the potentil benefits for aging and older adult population? Eur Geriatr Med. 2012;2:134–9.
46.
47.
Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001;33:62–9.PubMed
48.
Brisson MD, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CAMJ. 2010;182:1731–6.
49.
Schmid T, Pautex S, Lang PO. Acute and postherpetic neuralgia in the elderly: analysis of evidence for therapeutic options. Rev Med Suisse. 2012;8:1380–2.
50.
Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009;2:CD006866.
51.
Lang PO, Pautex S, Belmin J, Michel JP. Herpes-zoster related pain in aged individuals: how to manage it safely. Eur Geriatr Med. 2010;1:273–8.
52.
Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, Rabaud C, Rogeaux O, Strady C. Patient perspective on herpes zoster and its complication: an observational prospective study in patients aged over 50 years in general practice. Pain. 2012;153:342–9.PubMed
53.
Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, MacIntyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520–9.PubMed
54.
Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine. 2006;24:1308–14.PubMed
55.
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19:3076–90.PubMed
56.
Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88:562–70.PubMedCentralPubMed
57.
Choi WS, Kwon SS, Lee J, Choi SM, Lee JS, Eom JS, Sohn JW, Choeng HJ. Immunity and the burden of herpes zoster. J Med Virol. 2014;86:525–30.PubMed
58.
59.
Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761–5.PubMed
60.
de Greef SC, Lugner AK, van den Heuvel DM, Mooi FR, de Melker HE. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine. 2009;27:1932–7.
61.
Güriş D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, Wharton M, Livengood JR. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin Infect Dis. 1999;28:1230–7.
62.
de Greef SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands. Pediatr Infect Dis J. 2008;27:218–23.
63.
van Twillert I, van Gaans-van den Brink JA, Poelen MC, Helm K, Kuipers B, Schipper M, Boog CJ, Verheij TJ, Versteegh FG, van Els CA. Age related differences in dynamics of specific memory B cell populations after clinical pertussis infection. PLoS One. 2014;9:e85227.
64.
Stenger RM, Smits M, Kuipers B, van Gaans-van den Brink J, Poelen M, Boog CJ, van Els CA. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine. 2010;28:6637–46.
65.
Couzigou C, Flahault A. Is pertussis being considered as a cause of persistent cough among adults? Eur J Epidemiol. 2003;18:1013–5.PubMed
66.
Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R. Does this coughing adolescent or adult patient have pertussis? JAMA. 2010;2010:890–6.
67.
Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J. 2007;26:806–10.PubMed
68.
Halperin SA. Pertussis—a disease and vaccine for all ages. N Engl J Med. 2005;353:1615–7.PubMed
69.
Mertens PL, Stals FS, Schellekens JF, Houben AW, Huisman J. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis. 1999;18:242–7.PubMed
70.
Hu JJ, Lu CY, Chang LY, Huang CH, Chou CC, Huang FY, Lee CY, Huang LM. Survey of pertussis in patient with prolonged cough. J Microbiol Immunol Infect. 2006;39:54–8.PubMed
71.
Poland GA, Jacobson RM. The Age-Old struggle against the antivaccinationists. N Eng J Med. 2011;364:97–9.
72.
Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine preventable diseases. N Engl J Med. 2009;360:1981–8.
73.
World Health Organization (WHO). Diphtheria. Wkly Epidemiol Rec. 2006;81:21–32.
74.
McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136:660–6.PubMed
75.
Centers for Disease Control and Prevention (CDC). Tetanus surveillance—United States, 2001–2008. MMWR Morb Mortal Wkly Rep. 2011;60:365–9.
76.
Baeyens JP, Lang PO, Michel JP. Willingness to vaccinate and to be vaccinated in adults. Aging Clin Exp Res. 2009;21:244–9.PubMed
77.
Vaughn JA, Miller RA. Update on immunizations in adults. Am Fam Phys. 2011;84:1015–20.
78.
Michel JP. Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines. 2010;9:7–10.PubMed
79.
Sadaf A, Ricahrds JL, Glanz J, Salmon DA, Omer SB. A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy. Vaccine. 2013;31:4293–304.PubMed
80.
Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004;132:1005–22.PubMedCentralPubMed
81.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;41:6653–7.
82.
Suijkerbuijk AW, Lugnér AK, van Pelt W, Wallinga J, Verhoef LP, de Melker HE, de Wit GA. Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. Vaccine. 2012;30:5199–205.PubMed
83.
Verhoef L, Boot HJ, Koopmans M, Mollema L, Van Der Klis F, Reimerink J, et al. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995–1996 and 2006–2007. Epidemiol Infect. 2011;139:1172–80.PubMed
84.
McDonald SA, Mangen MJ, Suijkerbuijk A, Colzani E, Kretzschmar ME. Effects of an ageing population and the replacement of immune birth cohorts on the burden of hepatitis A in the Netherlands. BMC Infect Dis. 2013;13:120.PubMedCentralPubMed
85.
Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58:40–9.PubMed
86.
Erhart LM, Ernst KC. The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988–2007). Vaccine. 2012;30:6103–10.PubMed
87.
Field V, Gautret P, Schlagenhauf P, Burchard GD, Caumes E, Jensenius M, Castelli F, Gkrania-Klotsas E, Weld L, Lopez-Velez R, de Vries P, von Sonnenburg F, Loutan L, Parola P, EuroTravNet network. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis. 2010;10:330.PubMedCentralPubMed
88.
Gautret P, Gaudart J, Leder K, Schwartz E, Castelli F, Lim PL, Murphy H, Keystone J, Cramer J, Shaw M, Boddaert J, von Sonnenburg F, Parola P, GeoSentinel Surveillance Network. Travel-associated illness in older adults (>60 y). J Travel Med. 2012;19:169–77.
89.
Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006;6:130.PubMedCentralPubMed
90.
Baker MG, Thornley CN, Mills C, Roberts S, Perera S, Peters J, Kelso A, Barr I, Wilson N. Transmission of pandemic A/H1N1 2009 influenza on passenger aircraft: retrospective cohort study. BMJ. 2010;340:c2424.PubMedCentralPubMed
91.
Jacobs JA, Van Ranst M. Biometric fingerprinting for visa application: device and procedure are risk factors for infection transmission. J Travel Med. 2008;15:335–43.PubMed
92.
Michel JP, Lang PO, Baeyens JP. Flu vaccination policy in old adults: need for harmonization of national public health recommendations throughout Europe. Vaccine. 2009;27:182–3.PubMed
93.
Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86.PubMed
94.
Glezen PW, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499–505.PubMed
95.
Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, Singleton JA, Meltzer MI, Lu PJ, Bresee JS. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PLoS One. 2013;8:e66312.PubMedCentralPubMed
96.
Ferdinands JM, Gargiullo P, Haber M, Moore M, Belongia EA, Shay DK. Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies. Epidemiology. 2013;24:530–7.PubMed
97.
Lang PO, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64.PubMedCentralPubMed
98.
Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jiménez-Jorge S, Horváth JK, Daviaud I, Guiomar R, Necula G, Bella A, O’Donnell J, Głuchowska M, Ciancio BC, Nicoll A, Moren A. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. Euro Surveill. 2013;18(5):20390.
99.
Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother. 2012;8:851–62.PubMedCentralPubMed
100.
Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness—United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013;62:119–23.
101.
Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56:1363–9.PubMedCentralPubMed
102.
Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007:CD001269.
103.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;CD004876.
104.
Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165–74.PubMed
105.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2011;12:36–44.PubMed
106.
Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2006:CD004876.
107.
Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123:518–27.PubMed
108.
Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002;20:1831–6.PubMed
109.
Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29:9159–70.PubMed
110.
Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14:428–36.PubMed
111.
Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allo-static load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60:556–65.PubMed
112.
Ligthart GJ, Corberand JX, Fournier C, et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev. 1984;28:47–55.PubMed
113.
Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011;10:1143–67.PubMed
114.
Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16:217–25.PubMed
115.
Hausdorff WP, Feikin DR, Klugma KP. Hausdorff WP, Feikin DR, Klugma KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83–93.
116.
Blasi F, Mantero M, Santus PA, Tarsia P. Understanding the burden of pneumococcal diseases in adults. Clin Microbiol Infect. 2012;18(suppl. 5):1–8.
117.
Artz AS, Erschler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev. 2003;16:308–18.PubMedCentralPubMed
118.
Torling J, Hedlung J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine. 2003;22:96–103.PubMed
119.
World Health Organization (WHO). 23-valent pneumococcal polysaccharide vaccine: WHO position paper. Wkly Epidemiol Rec. 2008;83:373–84.
120.
Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, Rudolph K, Hennessy TW. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine. 2011;29(12):2287–95.
121.
Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
122.
Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;1:CD000422.
123.
Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48–58.PubMedCentralPubMed
124.
Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet. 2011;378:348–59.PubMed
125.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Eng J Med. 2003;348:1737–46.
126.
Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26:461–7.PubMed
127.
Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–54.PubMed
128.
Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–95.PubMed
129.
Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:468–72.PubMed
130.
Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92.PubMed
131.
Steenhoff AP, Shah SS, Ratner AJ, et al. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42:907–14.PubMed
132.
Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thoma B. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011;29:5195–202.PubMed
133.
Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25:6164–6.PubMed
134.
Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105:1776–83.PubMed
135.
Icardi G, Sticchi L, Bagnasco A, Iudici R, Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J Prev Med Hyg. 2012;53:78–84.PubMed
136.
Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66:378–83.PubMed
137.
138.
Sanford M, Keating GM. Zoster vaccine (Zostavax®). A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drug Aging. 2010;27:159–76.
139.
140.
Berger R, Trannoy E, Holländer G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis. 1998;178(Suppl 1):99–103.
141.
Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose–response trial. Vaccine. 2000;18:1700–6.PubMed
142.
Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15:314–9.PubMedCentralPubMed
143.
Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine. 2000;18:2915–20.PubMed
144.
Mills RTS, Levin MJ, Parrino J, Li X, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28:4204–9.PubMed
145.
Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccines. 2011;7:1130–6.
146.
Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–35.PubMedCentralPubMed
147.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med. 2005;352:2271–84.
148.
Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WWB, Zhang JH, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58:1634–41.PubMedCentralPubMed
149.
Simberkoff MSAR, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Safety of herpes zoster vaccine in the shingles prevention study a randomized trial. Ann Intern Med. 2010;152:545–54.PubMed
150.
Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caufield MJ, et al. Varicella-zoster virus-specific immune response to herpes zoster in elderly participants of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068–77.PubMedCentralPubMed
151.
Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine. 2007;25:1877–83.PubMed
152.
Vermeulen JNLJ, Tyring SK, Peters PH, Nunez M, Poland G, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30:904–10.PubMed
153.
Hayward ARBK, Levin MJ. Immune response to secondary immunization with live or Inactivated VZV vaccine in elderly adults. 1994;31–6(7):31–6.
154.
Hayward AR, Buda K, Jones M, White CJ, Levin MJ. Varicella zoster virus specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunol. 1996;9:241–5.PubMed
155.
Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weingerg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007;25:7087–93.PubMed
156.
Irwin MR, Olmstead R, Oxman MN. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. J Am Geriatr Soc. 2007;55:511–7.PubMed
157.
Kerzner B, Murray AV, Gheng E, Ifle R, Harvey PR, Tomlinson M, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55:1499–507.PubMed
158.
Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine. 2007;25:2139–44.PubMed
159.
Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320–8.PubMed
160.
van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27:1454–67.PubMed
161.
Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317–25.PubMed
162.
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326–37.PubMed
163.
Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280–8.PubMed
164.
Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccines. 2008;4:238–45.
165.
Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27:991–1004.PubMed
166.
de Boer PTPK, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31:1276–83.PubMed
167.
Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA. Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008;26:235–49.PubMed
168.
Lieu TA, Ray GT, Ortega-Sanchez I, Kleinman K, Rusinak D, Prosser LA. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics. 2009;27:1005–16.PubMed
169.
Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131:e1716–22.PubMed
170.
Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013;56:1248–54.PubMed
171.
Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, Edelman R, Edwards K, APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Eng J Med 2005;353:1555–63.
172.
Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R, APERT Study Group. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006;43:151–7.PubMed
173.
Theeten H, Rümke H, Hoppener FJP, Vilatimó R, Narejos S, Van Damme P, et al. Primary vaccination of adults with reduced antigen-content diphtheria–tetanus–acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria–tetanus–toxoid vaccines. Curr Med Res Opin. 2007;23:2729–39.PubMed
174.
Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine. 2005;23:3657–67.PubMed
175.
Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria–tetanus vaccine (Td) in adults. Vaccine. 2000;19:628–36.PubMed
176.
Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria–tetanus–acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18:2075–82.PubMed
177.
Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine. 2011;29:5932–9.PubMed
178.
ACIP Adult Immunization Work Group, Bridges CB, Woods L, Coyne-Beasley T, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older—United States, 2013. MMWR Surveill Summ. 2013;62(Suppl 1):9–19.
179.
Olender RM, Auranen K, Harkanen T, et al. High tetanus and diphtheria antitoxin concentrations in Finnish adults – time to new booster recommendations? Vaccine. 2009;27:5295–8.
180.
Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2011. MMWR. 2011;60:13–5.
181.
Centers for Disease Control and Prevention. (CDC). FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2011;60:1279–80.
182.
Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials. Vaccine. 2012;30:1721–8.PubMed
183.
McGarry LJ, Krishnarajah G, Hill G, Skornicki M, Pruttivarasin N, Masseria C, Arondekar B, Pelton SI, Weinstein MC. Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly. PLoS One. 2013;8:e67260.PubMedCentralPubMed
184.
Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, Nordin J, Baxter R, Naleway A, Donahue J, Weintraub E, Jacobsen SJ, Vaccine Safety Datalink (VSD) Team. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013;56:315–21.
185.
Weinberger B, Schirmer M, Gothe RM, Siebert U, Fuchs D, Grubeck-Loebenstein B. Recall responses to tetanus and diohtheria vaccination are frequently insufficent in elderly persons. PLos ONE. 2013;8:e82967.PubMedCentralPubMed
186.
World Health Organization (WHO). Hepatatis A. Wkly Epidemiol Rec. 2012;87:28–9.
187.
Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357:1685–94.PubMed
188.
Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328–34.PubMed
189.
D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med. 2006;2:78–83.
190.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT. Neuzil. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:193–213.
191.
Weston WM, Chanrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccine. 2009;5:858–66.
192.
Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A, Toronto Invasive Bacterial Diseases Network. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine. 2013;31:5863–71.
193.
Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–63.PubMed
194.
Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane database Syst Rev. 2010;(2):CD005187.
195.
Bayer R. The continuing tensions between individual rights and public health. Taking point on public health versus civil liberties. EMBO Rep. 2007;8:1099–103.PubMedCentralPubMed
196.
Poland GA, Belmin J, Langley J, Michel JP, Van Damme P, Wicker S. A global prescription for adult immunization: time is catching up with us. Vaccine. 2010;28:7137–9.PubMed
197.
Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, Stott DJ. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000;355:93–7.PubMed
198.
Metadata
Title
Vaccination in the Elderly: What Can Be Recommended?
Authors
Pierre-Olivier Lang
Richard Aspinall
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0193-1

Other articles of this Issue 8/2014

Drugs & Aging 8/2014 Go to the issue

Erratum

Erratum to: Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management

Original Research Article

Polypharmacy and Medication Regimen Complexity as Factors Associated with Hospital Discharge Destination Among Older People: A Prospective Cohort Study

Commentary

What Causes Some Patients with Drug-Induced QT Interval Prolongation to Develop Torsades de Pointes but Not Others? The Elusive Missing Link

Original Research Article

Determinants of Torsades de Pointes in Older Patients with Drug-Associated Long QT Syndrome: A Case-Control Study

Adis Drug Evaluation

Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia

Original Research Article

A Meta-Synthesis of Potentially Inappropriate Prescribing in Older Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits